BioWorld Asia

Aug. 18, 2004

Evolva Raises EUR12M To Drive Molecular Evolution Platform

Evolva SA raised €12 million in a Series A round to further develop its Watchmaker platform, which employs yeast artificial chromosomes and flow cytometry for the synthesis and selection of novel compounds. (BioWorld International) Read More

UK Clears Cloning Embryos For Extraction Of Stem Cells

Immune System Genes Merge To Beat Back Hepatitis C Virus

Lynx, Solexa Eyeing Merger After Gaining DNA Clusters

TopoTarget, NeuroSearch Form Agreement Around Cancer Drug

New Faces Constructing New EU Biotechnology Guidelines

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...